Clinical Trials Arena November 6, 2023
The global pharmaceutical industry experienced a 32% drop in company filings mentions of regenerative medicine in Q3 2023 compared with the previous quarter, with the highest share accounted for by Bayer with 560% year-on-year increase, according to GlobalData’s analysis of over 344 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, regenerative medicine was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of...
Today's Sponsors
Today's Sponsor